Experience

Arcus Biosciences

• United States
• Biotechnology
• 300 - 400 Employee

• Scientist, Cell Engineering

  • Nov 2021 - Present



Cleveland Clinic

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Postdoctoral Researcher

  • Apr 2017 - Oct 2021

  1. Targeting TET2 DNA Dioxygenase Deficient Cells in Leukemia and MDS. • Guan Y et al., Blood Cancer Discovery, 2021. PMID: 33681816 • Tiwari AD, Guan Y et al., Bioorganic & Medicinal Chemistry, 2021, PMID: 33894507. • Maciejewski J, Jha BK, Philips JG, Radivoyevitch T, Guan Y, and Tiwari AD. Antitumor TET2 Modulating Compounds, Publication Number: WO/2019/108796 (Patent). 2. Study the Effect of Ascorbic Acid on TET2 Mutant Myeloid Neoplasia. • Guan Y et al., Communication Biology, 2020 • Guan Y et al., Seminars in Hematology. 2021. • ClinicalTrials.gov Identifier: NCT03397173 (Clinical Trial) Show less



Case Western Reserve University

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Researcher

  • Oct 2015 - Apr 2017

  Postdoc in Cancer Biology, Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, OH. • Studied the role of tumor suppressor gene Receptor-type tyrosine-protein phosphatase T in colon cancer; • Drug screening and characterization to target glutamine metabolism enzyme GPT2 for cancer treatment. Postdoc in Cancer Biology, Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, OH. • Studied the role of tumor suppressor gene Receptor-type tyrosine-protein phosphatase T in colon cancer; • Drug screening and characterization to target glutamine metabolism enzyme GPT2 for cancer treatment.